A Leader in Scientific Breakthroughs
BrightFocus Foundation is a premier private funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. We are currently managing a nearly $65 million global portfolio of more than 260 scientific projects.
Learn more about grants awarded in the most current fiscal year. More than $25 million in funding for 106 new awards in FY2021.
BrightFocus Foundation will hold the third Glaucoma Fast Track to accelerate the fight for a cure by investing in promising young scientists in the field of vision research.
Extracellular vesicles isolated from the blood of people with Down syndrome-related Alzheimer’s disease have been shown to seed toxic tau species in the brains of normal mice, shedding light on the uptake and transmission of toxic tau.
BrightFocus-funded researchers were among the first to “map” the normal 3D structure of a protein called myocilin, which is abundant in the drainage pathway of the eye. Now, with a second grant, they’ve designed antibodies to help diagnose and treat myocilin misfolding as it contributes to glaucoma.